What is CEBINA?

At CEBINA (Central European Biotech Incubator and Accelerator), we go beyond a traditional biotechnology incubator – uniquely supporting life science entrepreneurs and young biotech companies through all stages of early company development, transforming promising new ideas into fully formed biotech companies that are attractive for investment. We offer a range of services: from state-of-the art laboratory and office rent, access to our highly experienced R&D, corporate and admin team, management mentoring and access to our network of private investors. We are also active in developing a portfolio of in-house spin-out companies through project/technology in-licensing and own research and innovation.

The CEBINA model is based on four pillars

  • Facility: Fully equipped laboratory and office space available for rent, in the heart of Vienna
  • Research & Development Team: Access to our highly experienced biotech team of experts
  • Corporate Service Team: Access to Business Development, IP, legal, Finance, HR and Administration
  • Management: Mentoring, corporate strategy, investor network

Meet the team

Eszter Nagy, MD, PhD

CEO, CSO Founder

20 years biotech experience and serial entrepreneur successfully raising >€40M VC financing & €16M non-dilutive funding

Co-founder, CEO Calyxha Biotechnologies GmbH; Co-founder, president Eveliqure Biotechnologies GmbH

Previously:  Co-founder & CSO Arsanis, Inc (IPO, NASDAQ 2017, now X4 Pharma); SVP Research, Intercell AG (now Valneva SAS)

Mag. Wolfgang Friedl


CEBINA operations, facility, investor relations and legal

Attorney at Law, founder and senior partner of viennalegal group

25 years experience in corporate law, national / international M&A, and financing with a strong focus on biotech

Sophie Zettl PhD

VP Business Development

Business development, intellectual property, PR and communications

15 years licensing / BD / IP experience in biotech, Pharma and University TTOs

Previously: Arsanis Inc, MedImmune / AstraZeneca, University College London, King’s College London

Gábor Nagy MD, PhD

Head Research & Technology Evaluation

12 years biotech R&D experience

Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH (co-founder), Intercell AG (now Valneva SAS)

Valéria Szijártó, MD, PhD

Head Preclinical & Translational research

8 years biotech R&D experience

Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH

Patrick Aisher

Strategic investor / investment advisor

Chairman of Kinled Holding investing in life science, digital & financial technologies

Direct investments in > 50 businesses, 24 exiting via IPO, trade sale or licensing

Partner in four life science funds with $300M AuM

Fabio Blom

Investment Committee Member

Resident Companies

Eveliqure Biotechnologies GmbH

Eveliqure is a game-changer amongst vaccine companies, championing new technologies to make the world safe from diarrhoea.

Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.


Calyxha Biotechnologies GmbH

Calyxha is a biotech start-up company developing novel therapies targeting tissue degeneration.

CALYXHA’s lead drug candidates have novel mechanisms of action that address pathologic pathways involved in tissue degeneration characteristics of the most common diseases.

Algonist Biotechnologies GmbH

Algonist Biotechnologies is the first start-up biotech company spun out from CEBINA.

Algonist is developing novel drugs against chronic pain that have comparable efficacy to opioids but do not lead to addiction.

CEBINA is actively evaluating potential new resident companies to join our portfolio

“CEBINA’s experienced biotech and business team can identify promising projects and mature them into biotech companies, making them attractive for further investment. As an investor, this provides me with an excellent opportunity to see promising, pre-vetted projects.”

Patrick Aisher, Chairman Kinled Holdings Ltd